Header Logo

Connection

James Mulshine to Dose-Response Relationship, Drug

This is a "connection" page, showing publications James Mulshine has written about Dose-Response Relationship, Drug.
  1. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res. 2005 May 15; 65(10):4181-90.
    View in: PubMed
    Score: 0.058
  2. Inhaled isotretinoin (13-cis retinoic acid) is an effective lung cancer chemopreventive agent in A/J mice at low doses: a pilot study. Clin Cancer Res. 2000 Aug; 6(8):3015-24.
    View in: PubMed
    Score: 0.042
  3. The correct dose: pharmacologically guided end point for anti-growth factor therapy. Cancer Res. 1992 May 01; 52(9 Suppl):2743s-2746s.
    View in: PubMed
    Score: 0.024
  4. Autocrine growth loops dependent on peptidyl alpha-amidating enzyme as targets for novel tumor cell growth inhibitors. Lung Cancer. 1999 Mar; 23(3):209-22.
    View in: PubMed
    Score: 0.010
  5. Dipyridamole mediated enhanced antiproliferative activity of 10-ethyl-10-deazaaminopterin (10-EDAM) against human lung cancer cell lines. J Cell Biochem Suppl. 1996; 24:165-72.
    View in: PubMed
    Score: 0.008
  6. Analysis of small cell lung cancer cell growth inhibition by 13-cis-retinoic acid: importance of bioavailability. Cell Growth Differ. 1995 May; 6(5):485-92.
    View in: PubMed
    Score: 0.007
  7. [Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo. Cancer Res. 1991 Apr 01; 51(7):1798-802.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.